Intra-Cellular Launches 26% To Record High, Breaking Out After Depression Drug Scores Big

Intra-Cellular Therapies (ITCI) stock rocketed and broke out Tuesday after its drug, Caplyta, topped expectations in a depression treatment study.

Caplyta is already approved as a schizophrenia treatment and to treat depressive episodes in people with bipolar disorder. Now, Intra-Cellular says Caplyta could treat a common form of depression known as major depressive disorder.